Compare HDL & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HDL | FLGT |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 867.4M |
| IPO Year | 2024 | 2016 |
| Metric | HDL | FLGT |
|---|---|---|
| Price | $16.43 | $26.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | 1.9K | ★ 207.9K |
| Earning Date | 11-26-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $820,865,000.00 | $315,549,000.00 |
| Revenue This Year | $10.64 | $16.84 |
| Revenue Next Year | $13.63 | $9.74 |
| P/E Ratio | $408.24 | ★ N/A |
| Revenue Growth | 8.02 | ★ 13.61 |
| 52 Week Low | $16.30 | $14.57 |
| 52 Week High | $29.94 | $31.04 |
| Indicator | HDL | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 38.71 | 41.37 |
| Support Level | $16.30 | $26.63 |
| Resistance Level | $17.00 | $28.26 |
| Average True Range (ATR) | 0.09 | 0.61 |
| MACD | -0.08 | -0.21 |
| Stochastic Oscillator | 6.41 | 19.94 |
Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.